Meningococcal Vaccinations

Nancy Crum-Cianflone, Eva Sullivan, Nancy Crum-Cianflone, Eva Sullivan

Abstract

Neisseria meningitidis, a gram-negative diplococcal bacterium, is a common asymptomatic nasopharyngeal colonizer that may infrequently lead to invasive disease in the form of meningitis or bacteremia. Six serogroups (A, B, C, W, X and Y) are responsible for the majority of invasive infections. Increased risk of disease occurs in specific population groups including infants, adolescents, those with asplenia or complement deficiencies, and those residing in crowded living conditions such as in college dormitories. The incidence of invasive meningococcal disease varies geographically with some countries (e.g., in the African meningitis belt) having both high endemic disease rates and ongoing epidemics, with annual rates reaching 1000 cases per 100,000 persons. Given the significant morbidity and mortality associated with meningococcal disease, it remains a major global health threat best prevented by vaccination. Several countries have implemented vaccination programs with the selection of specific vaccine(s) based on locally prevalent serogroup(s) of N. meningitidis and targeting population groups at highest risk. Polysaccharide meningococcal vaccines became available over 40 years ago, but are limited by their inability to produce immunologic memory responses, poor immunogenicity in infants/children, hyporesponsiveness after repeated doses, and lack of efficacy against nasopharyngeal carriage. In 1999, the first meningococcal conjugate vaccines were introduced and have been successful in overcoming many of the shortcomings of polysaccharide vaccines. The implementation of meningococcal conjugate vaccination programs in many areas of the world (including the massive campaign in sub-Saharan Africa using a serogroup A conjugate vaccine) has led to dramatic reductions in the incidence of meningococcal disease by both individual and population protection. Progressive advances in vaccinology have led to the recent licensure of two effective vaccines against serogroup B [MenB-4C (Bexsero) and MenB-FHbp (Trumenba)]. Overall, the evolution of novel meningococcal vaccines and the effective implementation of targeted vaccination programs has led to a substantial decrease in the burden of disease worldwide representing a major public health accomplishment.

Keywords: Meningococcal; Neisseria meningitidis; Review; Vaccinations.

Figures

Fig. 1
Fig. 1
Map of the predominant Neisseria meningitidis serogroups by geographic location

References

    1. Stephens DS, Apicella MA. Neisseria meningitidis. In: Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia, PA Elsevier Saunders Inc.; 2015. p. 2425-45.
    1. Marchiafava E, Celli A. Spra i micrococchi della meningite cerebrospinale epidemica. Gazz degli Ospedali. 1884;5:59.
    1. Weichselbaum A. Ueber die aetiologie der akuten meningitis cerebrospinalis. Fortschr Med. 1887;5:573.
    1. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:853–861. doi: 10.1016/S1473-3099(10)70251-6.
    1. Goldschneider I, Gotschlich EC, Artenstin MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327–1348. doi: 10.1084/jem.129.6.1327.
    1. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I. The role of humoral antibodies. J Exp Med. 1969;129:1307–1326. doi: 10.1084/jem.129.6.1307.
    1. Stephens DS. Uncloaking the meningococcus, the dynamics of meningococcal carriage and meningococcal disease. Lancet. 1999;353:941–942. doi: 10.1016/S0140-6736(98)00279-7.
    1. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378–1388. doi: 10.1056/NEJM200105033441807.
    1. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(Suppl 2):B3–B9. doi: 10.1016/j.vaccine.2011.12.062.
    1. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692–4700. doi: 10.1016/j.vaccine.2006.03.034.
    1. Thigpen MC, Whitney CG, Messonnier NE, et al. Emerging infections programs network. bacterial meningitis in the United States, 1998–2007. N Engl J Med. 2011;364:2016–2025. doi: 10.1056/NEJMoa1005384.
    1. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23:467–492. doi: 10.1128/CMR.00070-09.
    1. WHO Initiative for Vaccine Research (IVR): Meningococcal disease. Available at . Accessed 1 Feb 2016.
    1. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–39.
    1. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33:737–739. doi: 10.1086/322587.
    1. Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr. 1981;99:540–545. doi: 10.1016/S0022-3476(81)80250-8.
    1. Gianchecchi E, Torelli A, Piccini G, Piccirella S, Montomoli E. Neisseria meningitidis infection: who, when and where? Expert Rev Anti Infect Ther. 2015;13:1249–1263. doi: 10.1586/14787210.2015.1070096.
    1. Ashton FE, Ryan A, Diena B, et al. A new serogroup (L) of Neisseria meningitidis. J Clin Microbiol. 1983;17:722–727.
    1. Ding S, Ye R, Zhang H. Three new serogroups of Neisseria meningitidis. J Biol Stand. 1981;9:305–315. doi: 10.1016/S0092-1157(81)80056-X.
    1. Abio A, Neal KR, Beck CR. An epidemiological review of changes in meningococcal biology during the last 100 years. Pathog Glob Health. 2013;107:373–380. doi: 10.1179/2047773213Y.0000000119.
    1. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2007;31:101–107. doi: 10.1111/j.1574-6976.2006.00053.x.
    1. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30(Suppl 2):B26–B36. doi: 10.1016/j.vaccine.2011.12.032.
    1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl 2):B51–B63. doi: 10.1016/j.vaccine.2009.04.063.
    1. European Centre for Disease Prevention and Control . Surveillance of Invasive bacterial diseases in Europe 2008/2009. Stockholm: ECDC; 2011.
    1. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578–585. doi: 10.1093/cid/ciu881.
    1. Ceyan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration. Int J Infect Dis. 2012;16:e574–e582. doi: 10.1016/j.ijid.2012.03.011.
    1. Sáfadi MA, González-Ayala S, Jäkel A, et al. The epidemiology of meningococcal disease in Latin America, 1945–2010: an unpredictable and changing landscape. Epidemiol Infect. 2012;141:447–458. doi: 10.1017/S0950268812001689.
    1. Vyse A, Wolter JM, Chen J, et al. Meningococcal disease in Asia: an under-recognised public health burden. Epidemiol Infect. 2011;139:967–985. doi: 10.1017/S0950268811000574.
    1. Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544–552. doi: 10.1016/j.jinf.2015.07.007.
    1. Mustapha MM, Marsh JW, Harrison LH. Global epidemiology of capsular group W meningococcal disease (1970–2015): multifocal emergence and persistence of hypervirulent sequence type (ST)-11 clonal complex. Vaccine. 2016;34:1515–1523. doi: 10.1016/j.vaccine.2016.02.014.
    1. Zhou H, Liu W, Xu L, et al. Spread of Neisseria meningitidis serogroup W clone, China. Emerg Infect Dis. 2013;19:1496–1499. doi: 10.3201/eid1909.130160.
    1. Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344–348. doi: 10.1093/cid/cit243.
    1. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR. 2015;64:606–607.
    1. Cohn A, MacNeil J. The changing epidemiology of meningococcal disease. Infect Dis Clin N Am. 2015;29:667–677. doi: 10.1016/j.idc.2015.08.002.
    1. Centers for Disease Control and Prevention. Meningococcal Disease: Technical & Clinical Information. . Accessed 20 Feb 2016.
    1. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31:3–14. doi: 10.1111/j.1574-6976.2006.00051.x.
    1. Mutonga DM, Pimentel G, Muindi J, et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005–2006. Am J Trop Med Hyg. 2009;80:619–624.
    1. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740–780. doi: 10.1128/CMR.00048-09.
    1. Miller EC, Chase NM, Densen P, et al. Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and neisserial sepsis: c4 nephritic factor revisited. Clin Immunol. 2012;145:241–250. doi: 10.1016/j.clim.2012.09.007.
    1. Struijk GH, Bouts AHM, Rijkers GT, et al. Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant. 2013;13:819–820. doi: 10.1111/ajt.12032.
    1. Salit IE. Meningococcemia caused by serogroup W-135: association with hypogammaglobulinemia. Arch Intern Med. 1981;141:664–665. doi: 10.1001/archinte.1981.00340050110026.
    1. Miller L, Arakaki L, Ramautar A, et al. Elevated risk for invasive meningococcal disease among persons with HIV. Ann Intern Med. 2014;160:30–37. doi: 10.7326/P14-9011.
    1. Simon MS, Weiss D, Gulick RM. Invasive meningococcal disease in men who have sex with men. Ann Intern Med. 2013;159(4):300–301. doi: 10.7326/0003-4819-159-4-201308200-00674.
    1. Emonts M, Hazelzet JA, de Groot R, Hermans PW. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis. 2003;3:565–577. doi: 10.1016/S1473-3099(03)00740-0.
    1. Hibberd ML, Sumiya M, Summerfield JA, et al. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet. 1999;353:1049–1053. doi: 10.1016/S0140-6736(98)08350-0.
    1. Fijen CA, Bredius RG, Kuijper EJ, et al. The role of Fc gamma receptor polymorphisms and C3 in the immune defense against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol. 2000;120:338–345. doi: 10.1046/j.1365-2249.2000.01208.x.
    1. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998–2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184–191. doi: 10.1086/649209.
    1. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688–693. doi: 10.1001/jama.286.6.688.
    1. Cohn AC, MacNeil JR, Clark TA, et al; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.
    1. Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43:4811–4814. doi: 10.1128/JCM.43.9.4811-4814.2005.
    1. Aguilera J-F, Perrocheau A, Meffre C. Hahné S; W135 Working Group. Outbreak of the serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis. 2002;8:761–767. doi: 10.3201/eid0808.010422.
    1. Teyssou R, Muros-Le RE. Meningitis epidemics in Africa: a brief overview. Vaccine. 2007;25:A3–A7. doi: 10.1016/j.vaccine.2007.04.032.
    1. Moore PS, Hierholzer J, DeWitt W, Gouan K, et al. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningoccal meningitis. JAMA. 1990;264:1271–1275. doi: 10.1001/jama.1990.03450100061026.
    1. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979–983. doi: 10.1097/00006454-199710000-00015.
    1. Molesworth AM, Cuevas LE, Connor SJ, et al. Environmental risk and meningitis epidemics in Africa. Emerge Infect Dis. 2003;9:1287–1293. doi: 10.3201/eid0910.030182.
    1. Greenwood BM, Bradley AK, Wall RA. Meningococcal disease and season in sub-Saharan Africa. Lancet. 1985;2:829–830. doi: 10.1016/S0140-6736(85)90812-8.
    1. Artenstein MS, Gold R, Zimmerly JG, et al. Prevention of meningococcal disease by group C polysaccharide vaccine. N Engl J Med. 1970;282:417–420. doi: 10.1056/NEJM197002192820803.
    1. Vipond C, Care R, Feavers IM. History of meningococcal vaccines and their serological correlates of protection. Vaccine. 2012;30:B10–B17. doi: 10.1016/j.vaccine.2011.12.060.
    1. Borrow R. Advances with vaccination against Neisseria meningitidis. Trop Med Int Health. 2012;17:1478–1791. doi: 10.1111/j.1365-3156.2012.03085.x.
    1. Micoli F, Romano MR, Tontini M, et al. Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc Natl Acad Sci USA. 2013;1110:19077–19082. doi: 10.1073/pnas.1314476110.
    1. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50:S54–S65. doi: 10.1086/648966.
    1. Holst J, Oster P, Arnold R, et al. Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future. Hum Vaccin Immunother. 2013;9:1241–1253. doi: 10.4161/hv.24129.
    1. Caron F, du Châtelet IP, Leroy JP, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11:455–463. doi: 10.1016/S1473-3099(11)70027-5.
    1. Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR, Centers for Disease Control (CDC) Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–612.
    1. Kim DK, Bridges CB, Harriman KH, on behalf of the Advisory Committee on Immunization Practices. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2016. Ann Intern Med. 2016;164:184–94.
    1. Australian Immunisation Handbook. Australian Government Department of Health. 4.10 Meningococcal disease. Available at . Accessed 21 Feb 2016.
    1. Joint Committee on Vaccination and Immunisation. Available at . Accessed 21 Feb 2016.
    1. Green Book: Chapter 7 Immunization of Individuals with Underlying Medical Conditions; p. 49–56. Available at . Chapter 22 Meningococcal; p. 1–29. Available at . Chapter 12 Immunisation of healthcare and laboratory staff; p. 83–90. Available at .
    1. Geretti AM; BHIVA Immunization Writing Committee. British HIV Association guidelines for immunization of HIV-infected adults 2015. British HIV Association 2015. Available at .
    1. Public Agency of Canada-Canada Immunization Guide. Available at . Accessed 21 Feb 2016.
    1. Maiden MC, Ibarza-Pavon AB, Urwin R, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis. 2008;197:737–743. doi: 10.1086/527401.
    1. Daugla DM, Gami JP, Gamougam K, et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet. 2014;383:40–47. doi: 10.1016/S0140-6736(13)61612-8.
    1. Okwo-Bele J-M, LaForce FM, Borrow R, Preziosi M-P. Documenting the results of a successful partnership: a new meningococcal vaccine for Africa. Clin Infect Dis. 2015;61:S389–S390. doi: 10.1093/cid/civ592.
    1. WHO Weekly epidemiological record-Meningococcal A conjugate vaccine: updated guidance, February 2015;90, 57–68. Available at .
    1. Centers for Disease Control and Prevention Infant meningococcal vaccination: advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52–54.
    1. Al-Tawfiq JA, Memish ZA. The Hajj: updated health hazards and current recommendations for 2012. Euro Surveill. 2012;17. pii: 20295.
    1. Cramer JP, Wilder-Smith A. Meningococcal disease in travelers: update on vaccine options. Curr Opin Infect Dis. 2012;25:507–517. doi: 10.1097/QCO.0b013e3283574c06.
    1. Borrow R, Joseph H, Andrews N, et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine. 2000;19:1129–1132. doi: 10.1016/S0264-410X(00)00317-0.
    1. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181:761–764. doi: 10.1086/315284.
    1. MacNeil JR, Rubin L, Folaranmi T, Ortega-Sanchez IR, Patel M, Martin SW. Use of Serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171–1176. doi: 10.15585/mmwr.mm6441a3.
    1. McNamara LA, Shumate AM, Johnsen P, et al. Use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804. doi: 10.1542/peds.2014-4015.
    1. Pollard AJ, Riordan A, Ramsay M. Group B meningococcal vaccine: recommendations for UK use. Lancet. 2014;383:1103–1104. doi: 10.1016/S0140-6736(14)60226-9.
    1. Gossger N, Snape MD, Yu LM, et al. European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307:573–582. doi: 10.1001/jama.2012.85.
    1. Vesikari T, Esposito S, Prymula R, et al. EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825–835. doi: 10.1016/S0140-6736(12)61961-8.
    1. Vaccine Schedule. The European Centre for Disease Prevention and Control. Available at: . Accessed on 4 Jan 2016.
    1. Campbell H, Saliba V, Borrow R, Ramsay M, Ladhani SN. Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015. Euro Surveill. 2015;20. pii: 21188.
    1. Safadi MA, Bettinger JA, Moreno Meturana G, et al. Evolving meningococcal immunization strategies. Expert Rev Vaccines. 2015;14:505–517. doi: 10.1586/14760584.2015.979799.
    1. Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era—United States, 2000–2005. J Infect Dis. 2010;201:1208–1224. doi: 10.1086/651505.
    1. Academy of Pediatrics Committee on Infectious Diseases Updated recommendations on the use of meningococcal vaccines. Pediatrics. 2014;134:400. doi: 10.1542/peds.2014-1383.
    1. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect Immun. 2004;72:332–337. doi: 10.1128/IAI.72.1.332-337.2004.
    1. Lujan-Zilbermann J, Warshaw MG, Williams PL, International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1065 Protocol Team et al. Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus. J Pediatr. 2012;161:676–681. doi: 10.1016/j.jpeds.2012.04.005.
    1. American Academy of Pediatrics. [Meningococcal Infections.] In: Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Red Book: 2015 Report of the Committee on Infectious Diseases. 30th ed. Elk Grove Village: American Academy of Pediatrics; 2015. p. 547–57.
    1. Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35:81–93.
    1. Food and Drug Administration. Product approval information: package insert. Menactra (meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine). Sanofi Pasteur. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at . Accessed 21 Feb 2016.
    1. Centers for Disease Control and Prevention: Recommended Immunization Schedules for Persons Aged 0 Through 18 years; United States 2016. Available at: . Accessed 22 Feb 2016.
    1. Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011;29:1017–1022. doi: 10.1016/j.vaccine.2010.11.057.
    1. Zahlanie YC, Hammadi MM, Ghanem ST, Dbaibo S. Review of meningococcal vaccines with updates on immunization in adults. Hum Vaccin Immunother. 2014;10:995–1007. doi: 10.4161/hv.27739.
    1. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21:1350–1358. doi: 10.1002/pds.3321.
    1. De Wals P, Deceuninck G, Boucher RM, Ouakki M. Risk of Guillain-Barrè syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. Clin Infect Dis. 2008;46:e75–e77. doi: 10.1086/533469.
    1. Zheteyeva Y, Moro PL, Yue X, Broder K. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the vaccine adverse event reporting system. Am J Obstet Gynecol. 2013;208:e1–e6. doi: 10.1016/j.ajog.2013.02.027.
    1. Toxnet [Internet]. Bethesda (MD): National Library of Medicine (US): [Last Revision Date Mar 10, 2015]. Meningococcal Vaccines; LactMed Record Number: 168 [about 3 p]. Available at: .
    1. Anonymous Meningococcal disease. Secondary attack rate and chemoprophylaxis in the United States, 1974. JAMA. 1976;235:261–265. doi: 10.1001/jama.1976.03260290019018.
    1. Zalmanovici Trestioreanu A, Fraser A, Gafter-Gvili A, Paul M, Leibovici L. Antibiotics for preventing meningococcal infections. Cochrane Database Syst Rev. 2011; CD004785.
    1. Gardner P. Clinical practice. Prevention of meningococcal disease. N Engl J Med. 2006;355:1466–1473. doi: 10.1056/NEJMcp063561.
    1. Jorgensen JH, Crawford SA, Fiebelkorn KR. Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005;43:3162–3171. doi: 10.1128/JCM.43.7.3162-3171.2005.
    1. Prasad K, Karlupia N. Prevention of bacterial meningitis: an overview of Cochrane systematic reviews. Respir Med. 2007;101:2037–2043. doi: 10.1016/j.rmed.2007.06.030.
    1. Schwentker FF, Gelman S, Long PH. The treatment of meningococcal meningitis with sulfonamide: preliminary report. JAMA. 1937;108:1407–1408. doi: 10.1001/jama.1937.02780170025009.
    1. Shin SH, Kim KS. Treatment of bacterial meningitis: an update. Exp Opin Pharmacother. 2012;13:2189–2206. doi: 10.1517/14656566.2012.724399.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa